|
1) Synder PJ. Might testosterone actually reduce mortality？ JCEM. 2007; 93: 32-3
|
|
|
|
|
2) Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocrine Rev. 2003; 24: 313-40
|
|
|
|
|
|
3) Ding EL, Song Y, Malic VS, et al. Sex differences of endogeneous sex hormones and risk of type 2 diabetes. A systemic Review and Meta-analysis. JAMA. 2006; 295: 1288-99
|
|
|
|
|
4) Yanase T, Fan W, Kyoya K, et al. Androgens and metabolic syndrome: Lessons from androgen receptor knock out mouse. J Steroid Biochem Molec Biol. 2008; 109: 254-7
|
|
|
|
|
|
5) Kyle UG, Genton L, Hans D, et al. Age-related difference in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr. 2001; 55: 663-72
|
|
|
|
|
|
6) Synder PJ, Peachery H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000; 65: 2670-7
|
|
|
|
|
|
7) Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998; 83: 1886-992
|
|
|
|
|
|
8) Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-56
|
|
|
|
|
|
9) Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer. 2006; 106: 581-8
|
|
|
|
|
|
10) Baraga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006; 24: 3979-83
|
|
|
|
|
|
11) Page ST, Herbst KL, Amory JK, et al. Tes-tosterone administration suppresses adiponectin levels in men. J Androl. 2005; 26: 85-92
|
|
|
|
|
|
12) Sato T, Matsumoto T, Yamada T, et al. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun. 2003; 300: 167-71
|
|
|
|
|
|
13) Fan W, Yanase T, Nomura M, et al. Androgen receptor null male mice develop late-onset obesity due to decreased energy expenditure and lypolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes. 2005; 54: 1000-8
|
|
|
|
|
|
14) Jones MEE, Thorburn AW, Britt KL, et al. Aromatase deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A. 2000; 97: 12735-40
|
|
|
|
|
|
15) Xu X, De Pergola G, Bjontorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology. 1990; 126: 1229-34
|
|
|
|
|
|
16) Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002; 51: 2734-41
|
|
|
|
|
|
17) Xu A, Chan KW, Hoo RLC, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005; 280: 18073-80
|
|
|
|
|
|
18) Lin HY, Xu Q, Yeh S, et al. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes. 2005; 54: 1717-25
|
|
|
|
|
|
19) Fan W, Yanase T, Nishi Y, et al. Functional potentiation of leptin-stat2 signaling by the an- drogen receptor. Endocrinology. In press
|
|
|
|
|
|
20) Singh R, Artaza JN, Taylor WE, et al. Tes-tosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006; 147: 141-54
|
|
|
|
|
|
21) Wisniewski AB, Migeon CJ, Meyer-Bahlburg HFL, et al. Complete androgen insensitivity syndrome; Long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab. 2000; 85: 2664-9
|
|
|
|
|
|
22) Zitzmann M, Gromoll J, von Eckardstein A, et al. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia. 2003; 46: 31-9
|
|
|
|
|